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We have evaluated whether targeting the Src family kinase
cascade, an early component of B-cell receptor (BCR) sig-
naling, is an effective strategy to treat AIDS-related lym-
phoma (ARL). Src kinases are activated after ligation of the
BCR and they phosphorylate downstream signaling pro-
teins in tyrosine residues relaying B-cell signaling cascades
that lead to B cell activation and proliferation. These
kinases play an important role in lymphoma pathogene-
sis. We have shown that Src kinases are constitutively
active in diffuse large cell lymphoma (DLBCL) cells occur-
ring in immunocompetent individuals and inhibition of
these kinases using dasatinib inhibits proliferation of the
lymphoma cells.
Therefore, we postulated that targeting Src tyrosine
kinases pharmacologically would also inhibit the survival
and growth of the ARL cells. We tested the effect of dasat-
inib in 11 ARL cell lines, including six primary effusion
lymphomas, three EBV(+) DLBCL (immunoblastic) lym-
phomas, one EBV(-) DLBCL, and one EBV(+) Burkitt lym-
phoma. Cell proliferation and viability in the presence of
increasing doses of dasatinib were determined by the MTT
assay. In contrast to DLBCL in HIV-negative individuals,
most of which show sensitivity to dasatinib in the
nanomolar range, none of the ARL cell lines tested
showed sensitivity at doses as high as 1 uM. One EBV(+)
Hodgkin lymphoma cell line was also evaluated, and
found to be resistant to dasatinib treatment.
Non-AIDS DLBCLs have activation of SRC family kinases
(SFK). The activity of SFK including Src, Lyn, Hck and Blk
are invariably inhibited in both sensitive and resistant
DLBCL cell lines, whereas the activity of two downstream
signaling molecules, Syk and PLCγ2, are inhibited by
dasatinib only in sensitive cell lines. To determine the
molecular events that occur in ARL after dasatinib treat-
ment in comparison to non-AIDS HIV DLBCL, we per-
formed immunoblot analyses and phosphospecific flow
cytometry. Both primary effusion lymphoma (KSHV+)
cell lines evaluated (BC2 and VG-1) revealed very low
basal levels of total phosphotyrosine, which did not
change upon treatment with dasatinib. In contrast, the
EBV-associated (LCL-JP06 and BCKN-1) and the virus-
negative ARL cell line (BCHN-1) had significantly higher
basal tyrosine kinase activity. The HL cell line, L591 has
low but detectable level of phosphotyrosines. In these
non-PEL cell lines, dasatinib was able to inhibit tyrosine
phosphorylation at doses between 10 to 50 nM. In cell
lines that had total tyrosine phosphorylation, basal phos-
phorylation of Src and Lyn was detected, and their activi-
ties were efficiently inhibited by treatment with dasatinib.
When we examined ARL cell lines for phosphorylation of
Syk and PLCγ2, in those that have little or no basal phos-
photyrosines including the PEL cell lines (BC2 and VG-1)
and the HL cell line L591, cells did not respond to dasat-
inib treatment. In contrast, the DLBCL cell line BCHN-1
that had basal tyrosine phosphorylation, pSyk and p-
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PLCγ2 responded to BCR stimulation and dasatinib treat-
ment in a similar fashion to the control DLBCL cell lines.
However, in spite of this molecular response, this cell line
did not respond to the inhibitor at cellular level as no
inhibition in proliferation or viability was detected.
Our results indicate that in ARLs, inhibition of BCR sign-
aling is not detrimental to cellular survival or prolifera-
tion. These results suggest that viral proteins may provide
survival and proliferation signals through interaction with
cellular proteins that are further downstream from these
early events of BCR signaling. Lack of inhibition by dasat-
inib was unexpected and in marked contrast to observa-
tions made in DLBCL occurring in immunocompetent
individuals. These findings have therapeutic as well as
pathobiological implications. From the therapeutic stand-
point, while dasatinib is likely to be beneficial in lym-
phoma patients without HIV infection, this approach is
unlikely to be successful in patients with AIDS.Page 2 of 2
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